ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs MXN
20.7185
0.00%
Brent Oil
79.285
0.00%
Bitcoin
95,112.33
0.57%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Personalis Inc (PSNL)

  7. Personalis Inc (PSNL) Noticias

PSNL

Personalis (PSNL)

Personalis Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PSNL
FechaHoraFuenteTítuloSímboloCompañía
10/01/202520:20Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PSNLPersonalis Inc
07/01/202515:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSNLPersonalis Inc
07/01/202515:01Business WirePersonalis Reports Preliminary Fourth Quarter and Full Year 2024 RevenueNASDAQ:PSNLPersonalis Inc
27/12/202415:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PSNLPersonalis Inc
19/12/202408:00Business WirePersonalis Advances Business Strategy with Investment from Merck and Extends Collaboration with ModernaNASDAQ:PSNLPersonalis Inc
18/12/202415:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSNLPersonalis Inc
16/12/202407:00Business WirePersonalis and Tempus Expand Collaboration to BiopharmaNASDAQ:PSNLPersonalis Inc
20/11/202415:01Business WirePersonalis to Participate at Upcoming Investor ConferencesNASDAQ:PSNLPersonalis Inc
06/11/202415:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSNLPersonalis Inc
06/11/202415:01Business WirePersonalis Reports Third Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
05/11/202415:01Business WirePersonalis to Present at the Stifel 2024 Healthcare ConferenceNASDAQ:PSNLPersonalis Inc
23/10/202415:01Business WirePersonalis to Announce Third Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
16/09/202408:00Business WireESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD TestNASDAQ:PSNLPersonalis Inc
11/09/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSNLPersonalis Inc
30/08/202415:43Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PSNLPersonalis Inc
20/08/202415:27Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:PSNLPersonalis Inc
19/08/202415:05Business WirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSNLPersonalis Inc
16/08/202407:30Business WirePersonalis and Tempus Announce Expanded CollaborationNASDAQ:PSNLPersonalis Inc
07/08/202415:01Business WirePersonalis Reports Second Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
06/08/202415:05GlobeNewswire Inc.Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%NASDAQ:PSNLPersonalis Inc
31/07/202415:01Business WirePersonalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 ConferenceNASDAQ:PSNLPersonalis Inc
24/07/202415:01Business WirePersonalis to Announce Second Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
11/07/202408:00GlobeNewswire Inc.Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to TestingNASDAQ:PSNLPersonalis Inc
18/06/202415:01Business WirePersonalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution ConferenceNASDAQ:PSNLPersonalis Inc
13/06/202407:00Business WirePersonalis Provides Dial-in and Updated Date for ASCO Highlights Conference CallNASDAQ:PSNLPersonalis Inc
04/06/202415:05Business WireASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy MonitoringNASDAQ:PSNLPersonalis Inc
31/05/202408:05Business WirePersonalis Announces Start of Cancer MRD Testing Commercialization Collaboration with TempusNASDAQ:PSNLPersonalis Inc
22/05/202408:05Business WirePersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024NASDAQ:PSNLPersonalis Inc
08/05/202415:01Business WirePersonalis Reports First Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
24/04/202415:01Business WirePersonalis to Announce First Quarter 2024 Financial ResultsNASDAQ:PSNLPersonalis Inc
 Showing the most relevant articles for your search:NASDAQ:PSNL

Su Consulta Reciente

USOTC
AEAE
AltEnergy Acquisition (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados